RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol
Pharmacology, Toxicology and Pharmaceutical Science
4
5%
Agricultural and Biological Sciences
3
3%
Psychology
3
3%
Other
7
8%
Unknown
22
25%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2013.
All research outputs
#9,106,650
of 26,875,495 outputs
Outputs from Arthritis Care & Research
#1,958
of 3,066 outputs
Outputs of similar age
#48,237
of 133,835 outputs
Outputs of similar age from Arthritis Care & Research
#13
of 27 outputs
Altmetric has tracked 26,875,495 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,066 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.6. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 133,835 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
